Pharmacopeia discovers new respiratory disease therapy, gets milestone payment

By Elaine Rigoli

Tampa, Fla., April 11 - Pharmacopeia announced that Schering-Plough has selected for further development a compound being evaluated as a potential treatment for respiratory disease.

The drug was identified through an ongoing collaboration between the two companies. Under terms of the collaboration, the development triggers an undisclosed milestone payment to Pharmacopeia, according to a news release.

Pharmacopeia and Schering-Plough have been collaborating on the discovery of novel compounds for further research and development by Schering-Plough since 1994.

Pharmacopeia is eligible to receive milestone payments related to successful advancement of compounds and future royalties on sales of resulting products.

This respiratory-disease compound is the latest in a series of drug candidates jointly discovered by the collaboration that are currently in development, the release said.

Kenilworth, N.J.-based Schering-Plough focuses on cardiovascular and metabolic diseases, central nervous system disorders, infectious diseases, inflammatory diseases, oncology and respiratory diseases

Princeton, N.J.-based Pharmacopeia discovers and develops novel small-molecule therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.